{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:57:00Z","timestamp":1764997020204,"version":"3.41.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Science and Technology (DST), Government of India","award":["95996."],"award-info":[{"award-number":["95996."]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.pharep.2014.08.010","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T05:33:58Z","timestamp":1410413638000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population"],"prefix":"10.1007","volume":"67","author":[{"given":"Annan Sudarsan","family":"Arun Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasamurthy Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurusamy","family":"Umamaheswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramasamy","family":"Kesavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayaraman","family":"Balachandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrasekaran","family":"Adithan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.08.010_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"year":"2011","author":"World Health Organization","series-title":"Global atlas on cardiovascular disease prevention and control","key":"10.1016\/j.pharep.2014.08.010_bib0010"},{"key":"10.1016\/j.pharep.2014.08.010_bib0015","doi-asserted-by":"crossref","first-page":"15983","DOI":"10.1074\/jbc.M100439200","article-title":"Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids","volume":"276","author":"Node","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2014.08.010_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharep.2014.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/01.RES.0000017727.35930.33","article-title":"Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids","volume":"90","author":"Sun","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2014.08.010_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.103.052787","article-title":"Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways","volume":"307","author":"Wang","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2014.08.010_bib0035","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.105.006452","article-title":"Impact of cyp2c9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?","volume":"33","author":"Rodrigues","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2014.08.010_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of cyp2c8 and cyp2c9, respectively","volume":"30","author":"Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2014.08.010_bib0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of cyp2j2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2014.08.010_bib0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.addr.2011.03.006","article-title":"The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases","volume":"63","author":"Xu","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharep.2014.08.010_bib0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/gtmb.2010.0170","article-title":"Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population","volume":"15","author":"Arun Kumar","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.pharep.2014.08.010_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/46816","article-title":"Cytochrome P450 2C is an EDHF synthase in coronary arteries","volume":"401","author":"Fisslthaler","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharep.2014.08.010_bib0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/gtmb.2012.0256","article-title":"CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations","volume":"17","author":"Wu","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.pharep.2014.08.010_bib0075","first-page":"665","article-title":"Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from South India","volume":"123","author":"Rosemary","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.pharep.2014.08.010_bib0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2014.08.010_bib0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2006.11.001","article-title":"Synergistic effect of Cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction","volume":"195","author":"Liu","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2014.08.010_bib0090","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00008571-200312000-00002","article-title":"Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction","volume":"13","author":"Yasar","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0095","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s11033-012-2170-2","article-title":"Endothelial nitric oxide synthase gene polymorphisms and the risk of acute myocardial infarction in a South Indian population","volume":"40","author":"Arun Kumar","year":"2013","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.pharep.2014.08.010_bib0100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tcm.2006.04.001","article-title":"Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease","volume":"16","author":"Spiecker","year":"2006","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharep.2014.08.010_bib0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.RES.88.1.44","article-title":"Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries","volume":"88","author":"Fleming","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.pharep.2014.08.010_bib0110","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1152\/ajpheart.2001.280.6.H2430","article-title":"EET homologs potently dilate coronary microvessels and activate BK(Ca) channels","volume":"280","author":"Zhang","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharep.2014.08.010_bib0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/FPC.0b013e3282fd1287","article-title":"Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke","volume":"18","author":"Marciante","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0120","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000143832.91812.60","article-title":"Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2","volume":"110","author":"Spiecker","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2014.08.010_bib0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1373\/clinchem.2006.084756","article-title":"The \u221250G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen risk and cardiovascular health study","volume":"53","author":"Hoffmann","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.pharep.2014.08.010_bib0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FPC.0b013e32809913ea","article-title":"CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the atherosclerosis risk in communities (ARIC) study","volume":"17","author":"Lee","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FPC.0b013e3283485eb2","article-title":"Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease","volume":"21","author":"Xu","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2261-8-41","article-title":"The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile","volume":"8","author":"Borgel","year":"2008","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharep.2014.08.010_bib0145","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2217\/pgs.10.96","article-title":"Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort","volume":"11","author":"Haschke-Becher","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.fpc.0000236335.57046.c8","article-title":"The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9","volume":"17","author":"Visser","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharep.2014.08.010_bib0155","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.amjhyper.2005.04.019","article-title":"The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension","volume":"18","author":"Dreisbach","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharep.2014.08.010_bib0160","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1373\/clinchem.2004.038034","article-title":"CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction","volume":"50","author":"Funk","year":"2004","journal-title":"Clin Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:41Z","timestamp":1752611741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.08.010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1734114014002710"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.08.010","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}